Please login to the form below
Zaltrap
This page shows the latest Zaltrap news and features for those working in and with pharma, biotech and healthcare.
Rise in cancer therapy costs 'unsustainable' says oncologist
Saltz has been a vocal critic of cancer drug pricing for some time, and was one of the architects of MSKCC's decision three years ago not to prescribe Zaltrap ... Zaltrap was also turned down by the UK's National Institute for Health and Care Excellence
Latest news
-
England's Cancer Drugs Fund: Fixing a broken system
One of these has been Sanofi, whose prostate cancer drug Jevtana (cabazitaxel) and bowel cancer medicine Zaltrap (aflibercept) were deemed too expensive for both the specialist CDF and for NICE. ... Sanofi's Zaltrap (aflibercept):. second line treatment
-
Pharma condemns Cancer Drugs Fund cuts
Sanofi's Zaltrap is one of several drugs to be delisted from England's Cancer Drugs Fund. ... cancer. In the past 18 months there have been 1, 154 and 707 requests submitted to the CDF for Zaltrap and Jevtana respectively.
-
NHS names drugs to be re-evaluated for Cancer Drugs Fund
Prostate cancer. Zaltrap (aflibercept). Colorectal cancer. Takeda. Adcetris (brentuximab vedotin). Lymphoma (3 indications). .
-
Charity demands action on cancer drug prices in UK
Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
-
England's Cancer Drugs Fund: Naughty or NICE?
Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
More from news
Approximately 3 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
The reality of real-world evidence
Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Account Director, Medical Education
-
Salary TBC
-
Director – Healthcare PR
-
Salary TBC
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Competitive salary and benefits
- NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
PMHub
Swordfish Advertising
At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...
Latest intelligence
- 04 A Healthy Ambience
- Creating a Lifeline to the New Digital User...
- 03 Health Services
- How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
Quick links
Infographics
